BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 19195631)

  • 1. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR, a multipurpose nuclear receptor.
    Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
    Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of FXR in disorders of bile acid homeostasis.
    Eloranta JJ; Kullak-Ublick GA
    Physiology (Bethesda); 2008 Oct; 23():286-95. PubMed ID: 18927204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
    Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
    Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
    Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
    FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FXR: a metabolic regulator and cell protector.
    Wang YD; Chen WD; Moore DD; Huang W
    Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
    Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
    Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
    Swales KE; Korbonits M; Carpenter R; Walsh DT; Warner TD; Bishop-Bailey D
    Cancer Res; 2006 Oct; 66(20):10120-6. PubMed ID: 17047076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice.
    Martin IV; Schmitt J; Minkenberg A; Mertens JC; Stieger B; Mullhaupt B; Geier A
    Biol Chem; 2010 Dec; 391(12):1441-9. PubMed ID: 20868235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.
    Zhang S; Liu Q; Wang J; Harnish DC
    Biochem Biophys Res Commun; 2009 Feb; 379(2):476-9. PubMed ID: 19118524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
    Fiorucci S; Mencarelli A; Palladino G; Cipriani S
    Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.
    Mencarelli A; Renga B; Migliorati M; Cipriani S; Distrutti E; Santucci L; Fiorucci S
    J Immunol; 2009 Nov; 183(10):6657-66. PubMed ID: 19880446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
    Duran-Sandoval D; Cariou B; Fruchart JC; Staels B
    Biochimie; 2005 Jan; 87(1):93-8. PubMed ID: 15733743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.